# US 2026/0242394 A1 · Usp2 inhibitors and methods of using the same for the treatment of diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0242394 A1
- Document ID: US20260242394A1
- Status: Published application
- Kind: A1
- Application number: 19/472,280
- Filed: 2024-04-05
- Published: 2026-08-20
- Earliest claimed: 2023-04-06
- Assignees: Icahn School of Medicine at Mount Sinai; Beth Israel Deaconess Medical Center, Inc.; The Trustees of Columbia University in the City of New York
- Applicants: Icahn School of Medicine At Mount Sinai; Beth Israel Deaconess Medical Center, Inc.; The Trustees of Columbia University In the City of New York
- Inventors: Jian Jin; Wenyi Wei; Wei Gu; Yan Xiong; Xiaoping Hu; Fabin Dang; Jingjie Yi
- Web page: https://patentgrep.com/patent/US20260242394A1

## CPC

- C07D 495/04: Ortho-condensed systems
- A61K 31/18: Sulfonamides (compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63)
- A61K 31/381: having five-membered rings
- A61K 31/4168: having a nitrogen attached in position 2, e.g. clonidine
- A61K 31/426: 1,3-Thiazoles
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/428: condensed with carbocyclic rings
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/5375: 1,4-Oxazines, e.g. morpholine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/14: for RNA viruses
- C07C 311/21: having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07D 233/88: Nitrogen atoms, e.g. allantoin
- C07D 277/38: Nitrogen atoms
- C07D 277/46: by carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D 277/82: Nitrogen atoms
- C07D 295/13: to an acyclic saturated chain
- C07D 333/36: Nitrogen atoms
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 491/048: the oxygen-containing ring being five-membered
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

Disclosed are small molecule ubiquitin carboxyl-terminal hydrolase 2 (USP2) inhibitors which display great potency in inhibiting cancer cell proliferation by elevating wild type P53 levels, reducing cyclin D levels or blocking ACE2 dependent virus from entering host cells by reducing ACE2 levels. The results indicate that these USP2 inhibitors have potential to be used in treating various diseases, including cancer and virus infection depending on ACE2.

## Claims

### Claim 1

A USP2 inhibitor, comprising a compound of Formula (I):
wherein
A is C═O, CH2 or absent;
Y is a bond, or a bivalent moiety selected from —N(R4)—, —N(R4)—C1-C3 alkylene-, —N(R4)—S(O)2—, —N(R4)—C(O)—, —S(O)2— N(R4)—, or —C(O)—N(R4)—;
Ring B is a ring structure selected from C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl;
Ring C is absent, or a ring structure selected from C6-C10 aryl, or 5-10 membered heteroaryl;
Ring D is a ring structure selected from C5-C10 aryl, 5-10 membered heteroaryl or 3-12 membered heterocyclic;
Q1 and Q2 are independently selected from absent, O, NR5, C1-C3 alkylene, C2-C6 alkenylene, or C2-C6 alkynylene, where each said C1-C3 alkylene, C2-C6 alkenylene, or C2-C6 alkynylene is optionally substituted with one or more of halogen, cyano, hydroxyl, oxo, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxyl, or C3-C6 cycloalkoxy;
each R1, each R2, and each R3 are independently selected from H, halogen, cyano, oxo, OR6, NR6R7, C(O)OR6, C(O)NR6R7, S(O)2NR6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R1, two adjacent R2, or two adjacent R3, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
each R4, each R5, each R6 and each R7 are independently selected from H, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic; or R6 and R7, together with the atoms to which they are attached, optionally form 4-8 membered heterocyclic;
each R8 and each R9 are independently selected from H, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-Cia aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic; or R8 and R9, together with the atoms to which they are attached, optionally form a 4-8 membered heterocyclic; and
n is 0, 1, 2, 3, or 4;
m is 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9; and
x is 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9; and
pharmaceutically acceptable salts or tautomers thereof.

### Claim 2 (depends on 1)

The USP2 inhibitor of claim 1 wherein the compound is a compound of Formula (I-A):
wherein
R10 is selected from H, OR6, NR6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; and
A is C═O, CH2 or absent;
Y is a bond, or a bivalent moiety selected from —N(R4)—, —N(R4)—C1-C3 alkylene-, —N(R4)—S(O)2—, —N(R4)—C(O)—, —S(O)2— N(R4)—, or —C(O)—N(R4)—;
Ring B is a ring structure selected from C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl;
Ring D is a ring structure selected from C5-C10 aryl, 5-10 membered heteroaryl or 3-12 membered heterocyclic;
Q1 and Q2 are independently selected from absent, O, NR5, C1-C3 alkylene, C2-C6 alkenylene, or C2-C6 alkynylene, where each said C1-C3 alkylene, C2-C6 alkenylene, or C2-C6 alkynylene is optionally substituted with one or more of halogen, cyano, hydroxyl, oxo, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxyl, or C3-C6 cycloalkoxy;
R1 and R2 are each independently selected from H, halogen, cyano, oxo, OR6, NR6R7, C(O)OR6, C(O)NR6R7, S(O)2NR6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R1, two adjacent R2, or two adjacent R3, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
R4 and R5 are independently selected from H or C1-C6 alkyl;
each of R6 and R7 are independently selected from H, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic; or R6 and R7, together with the atoms to which they are attached, optionally form 4-8 membered heterocyclic;
each R8 and each R9 are independently selected from H, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-Cia aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic; or R8 and R9, together with the atoms to which they are attached, optionally form a 4-8 membered heterocyclic; and
n is 0, 1, 2, 3, or 4;
m is 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9; and
pharmaceutically acceptable salts or tautomers thereof.

### Claim 3 (depends on 2)

The USP2 inhibitor of claim 2, wherein the compound is a compound of Formula (I-A-1):
wherein
X is CH or N;
Z is C═O or SO2;
Ring B is a ring structure selected from C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl;
R1, R2, and R3 are independently selected from H, halogen, cyano, oxo, OR6, NR6R7, C(O)OR6, C(O)NR6R7, S(O)2NR6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R1, two adjacent R2, or two adjacent R3, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
R6 and R7 are each independently selected from H, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic; or R6 and R7, together with the atoms to which they are attached, optionally form 4-8 membered heterocyclic;
R8 and R9 are each independently selected from H, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic; or R8 and R9, together with the atoms to which they are attached, optionally form 4-8 membered heterocyclic;
R10 is selected from H, OR6, NR6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; and
n is 0, 1, 2, 3, or 4;
m is 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9; and
pharmaceutically acceptable salts or tautomers thereof.

### Claim 4 (depends on 3)

The USP2 inhibitor of claim 3, wherein the compound is a compound of Formula (I-A-2):
wherein
Ar1 is selected from C6-C10 aryl or 5-10 membered heteroaryl;
X is CH or N;
Z is C═O or SO2;
R1, R2, and R3 are independently selected from H, halogen, cyano, oxo, OR6, NR6R7, C(O)OR6, C(O)NR6R7, S(O)2NR6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R1, two adjacent R2, or two adjacent R3, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
R6 and R7 are each independently selected from H, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic; or R6 and R7, together with the atoms to which they are attached, optionally form 4-8 membered heterocyclic;
R8 and R9 are each independently selected from H, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, C1-C6 alkyl, C1—C6 heteroalkyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic; or R8 and R9, together with the atoms to which they are attached, optionally form 4-8 membered heterocyclic;
R10 is selected from H, OR6, NR6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; and
n is 0, 1, 2, 3, or 4;
m is 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9; and
pharmaceutically acceptable salts or tautomers thereof.

### Claim 5 (depends on 4)

The compound of claim 4, wherein Ar1 is selected from the group consisting of

### Claim 6 (depends on 4)

The USP2 inhibitor of claim 4, wherein the compound is a compound of Formulae (I-A-3), (I-A-4) or (I-A-5):
wherein
each R11 is independently selected from H, halogen, cyano, OR6, NR6R7, C(O)OR8, C(O)NR8R9, S(O)2NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R11, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
each R12 is independently selected from H, halogen, cyano, OR6, NR6R7, C(O)OR6, C(O)NR6R7, S(O)2NR6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R12, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
X is CH or N;
Z is C═O or SO2;
R1 is selected from H, halogen, cyano, oxo, OR6, NR6R7, C(O)OR6, C(O)NR6R7, S(O)2NR6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R1, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
R6 and R7 are each independently selected from H, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic; or R6 and R7, together with the atoms to which they are attached, optionally form 4-8 membered heterocyclic;
R8 and R9 are each independently selected from H, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic; or R8 and R9, together with the atoms to which they are attached, optionally form 4-8 membered heterocyclic;
R10 is selected from H, OR6, NR6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; and
n is 0, 1, 2, 3, or 4;
m is 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9; and
pharmaceutically acceptable salts or tautomers thereof.

### Claim 7 (depends on 6)

The USP2 inhibitor of claim 6, wherein the compound is a compound of Formulae (I-A-6), (I-A-7) or (I-A-8):
wherein
Z is C═O or SO2;
each R11 is independently selected from H, halogen, cyano, OR6, NR6R7, C(O)OR8, C(O)NR8R9, S(O)2NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R11, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
each R12 is independently selected from H, halogen, cyano, OR6, NR6R7, C(O)OR6, C(O)NR6R7, S(O)2NR6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R12, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
R1 is selected from H, halogen, cyano, oxo, OR6, NR6R7, C(O)OR6, C(O)NR6R7, S(O)2NR6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R1, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
R6 and R7 are each independently selected from H, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic; or R6 and R7, together with the atoms to which they are attached, optionally form 4-8 membered heterocyclic;
R8 and R9 are each independently selected from H, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic; or R8 and R9, together with the atoms to which they are attached, optionally form 4-8 membered heterocyclic;
R10 is selected from H, OR6, NR6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; and
n is 0, 1, 2, 3, or 4;
m is 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9; and
pharmaceutically acceptable salts or tautomers thereof.

### Claim 8 (depends on 7)

The USP2 inhibitor of claim 7, wherein the compound is a compound of Formulae (I-A-9), (I-A-10) or (I-A-11):
wherein
Z is C═O or SO2;
each R11 is independently selected from H, halogen, cyano, OR6, N6R7, C(O)OR8, C(O)NR8R9, S(O)2NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R11, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
each R12 is independently selected from H, halogen, cyano, OR6, NR6R7, C(O)OR6, C(O)NR6R7, S(O)2NR6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R12, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
R1 is selected from H, halogen, cyano, oxo, OR6, NR6R7, C(O)OR6, C(O)NR6R7, S(O)2NR6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R1, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
R6 and R7 are each independently selected from H, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic; or R6 and R7, together with the atoms to which they are attached, optionally form 4-8 membered heterocyclic;
R8 and R9 are each independently selected from H, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic; or R8 and R9, together with the atoms to which they are attached, optionally form 4-8 membered heterocyclic;
R10 is selected from H, OR6, NR6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; and
n is 0, 1, 2, 3, or 4;
m is 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9; and
pharmaceutically acceptable salts or tautomers thereof.

### Claim 9 (depends on 7)

The USP2 inhibitor of claim 7, wherein the compound is a compound of Formulae (I-A-12), (I-A-13), (I-A-14), (I-A-15), (I-A-16) or (I-A-17):
wherein
R10a is selected from H, C1-C6 alkyl, C2-C6 alkenyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic, where each said C1-C6 alkyl, C2-C6 alkenyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic is optionally substituted with halogen, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl.
each R11 is independently selected from H, halogen, cyano, OR6, NR6R7, C(O)OR8, C(O)NR8R9, S(O)2NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R11, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
each R12 is independently selected from H, halogen, cyano, OR6, NR6R7, C(O)OR6, C(O)NR6R7, S(O)2NR6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R12, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
R1 is selected from H, halogen, cyano, oxo, OR6, NR6R7, C(O)OR6, C(O)NR6R7, S(O)2NR6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R1, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
R6 and R7 are each independently selected from H, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic; or R6 and R7, together with the atoms to which they are attached, optionally form 4-8 membered heterocyclic;
R8 and R9 are each independently selected from H, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic; or R8 and R9, together with the atoms to which they are attached, optionally form 4-8 membered heterocyclic; and
n is 0, 1, 2, 3, or 4;
m is 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9; and
pharmaceutically acceptable salts or tautomers thereof.

### Claim 10

A USP2 inhibitor, comprising a compound of Formulae (I-B1), (I-B2) or (I-B3):
wherein
Ar2 is selected from C6-C10 aryl, or 5-10 membered heteroaryl;
Ar3 is selected from 7-10 membered bicyclic heteroaryl;
Ar4 is selected from 5-6 membered monocyclic heteroaryl;
Ar5 is selected from C6-C10 aryl, or 5-10 membered heteroaryl;
each R13 is independently selected from H, halogen, cyano, OR6, N6R7, C(O)OR6, C(O)NR6R7, S(O)2N6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R13, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
A is C═O, CH2 or absent;
Ring D is a ring structure selected from C5-C10 aryl, 5-10 membered heteroaryl or 3-12 membered heterocyclic;
Y is a bond, or a bivalent moiety selected from —N(R4)—, —N(R4)—C1-C3 alkylene-, —N(R4)—S(O)2—, —N(R4)—C(O)—, —S(O)2— N(R4)—, or —C(O)—N(R4)—;
Q1 and Q2 are independently selected from absent, O, NR5, C1-C3 alkylene, C2-C6 alkenylene, or C2-C6 alkynylene, where each said C1-C3 alkylene, C2-C6 alkenylene, or C2-C6 alkynylene is optionally substituted with one or more of halogen, cyano, hydroxyl, oxo, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxyl, or C3-C6 cycloalkoxy;
R1 is selected from H, halogen, cyano, oxo, OR6, NR6R7, C(O)OR6, C(O)NR6R7, S(O)2NR6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R1, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
R6 and R7 are each independently selected from H, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic; or R6 and R7, together with the atoms to which they are attached, optionally form 4-8 membered heterocyclic;
R8 and R9 are each independently selected from H, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic; or R8 and R9, together with the atoms to which they are attached, optionally form 4-8 membered heterocyclic;
each R11 is independently selected from H, halogen, cyano, OR6, NR6R7, C(O)OR8, C(O)NR8R9, S(O)2NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R11, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
each R12 is independently selected from H, halogen, cyano, OR6, NR6R7, C(O)OR6, C(O)NR6R7, S(O)2NR6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R12, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
n is 0, 1, 2, 3, or 4;
m is 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9; and
x is 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9; and
pharmaceutically acceptable salts or tautomers thereof.

### Claim 11 (depends on 10)

The USP2 inhibitor of claim 10, wherein the compound is a compound of Formulae (I-B1), (I-B2) or (I-B3-1):
wherein
Ar2 is selected from C6-C10 aryl, or 5-10 membered heteroaryl;
Ar3 is selected from 7-10 membered bicyclic heteroaryl;
Ar4 is selected from 5-6 membered monocyclic heteroaryl;
Ar5 is selected from C6-C10 aryl, or 5-10 membered heteroaryl;
Ring D is a ring structure selected from C5-C10 aryl, 5-10 membered heteroaryl or 3-12 membered heterocyclic;
each R13 is independently selected from H, halogen, cyano, OR6, N6R7, C(O)OR6, C(O)NR6R7, S(O)2NR6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R13, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
A is C═O, CH2 or absent;
Z is C═O or SO2;
Q1 and Q2 are independently selected from absent, O, NR5, C1-C3 alkylene, C2-C6 alkenylene, or C2-C6 alkynylene, where each said C1-C3 alkylene, C2-C6 alkenylene, or C2-C6 alkynylene is optionally substituted with one or more of halogen, cyano, hydroxyl, oxo, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxyl, or C3-C6 cycloalkoxy;
R1 is selected from H, halogen, cyano, oxo, OR6, NR6R7, C(O)OR6, C(O)NR6R7, S(O)2NR6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R1, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
R6 and R7 are each independently selected from H, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic; or R6 and R7, together with the atoms to which they are attached, optionally form 4-8 membered heterocyclic;
R8 and R9 are each independently selected from H, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic; or R8 and R9, together with the atoms to which they are attached, optionally form 4-8 membered heterocyclic;
each R11 is independently selected from H, halogen, cyano, OR6, NR6R7, C(O)OR8, C(O)NR8R9, S(O)2NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R11, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
each R12 is independently selected from H, halogen, cyano, OR6, NR6R7, C(O)OR6, C(O)NR6R7, S(O)2NR6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R12, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
n is 0, 1, 2, 3, or 4;
m is 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9; and
x is 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9; and
pharmaceutically acceptable salts or tautomers thereof.

### Claim 12 (depends on 11)

The USP2 inhibitor of claim 11, wherein the compound is a compound of Formulae (I-B1-2), (I-B2-2) or (I-B3-2):
wherein
Ar2 is selected from C6-C10 aryl, or 5-10 membered heteroaryl;
Ar3 is selected from 7-10 membered bicyclic heteroaryl;
Ar4 is selected from 5-6 membered monocyclic heteroaryl;
Ar5 is selected from C6-C10 aryl, or 5-10 membered heteroaryl;
Ring D is a ring structure selected from C5-C10 aryl, 5-10 membered heteroaryl or 3-12 membered heterocyclic;
each R13 is independently selected from H, halogen, cyano, OR6, NR6R7, C(O)OR6, C(O)NR6R7, S(O)2NR6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R13, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
Z is C═O or SO2;
R1 is selected from H, halogen, cyano, oxo, OR6, NR6R7, C(O)OR6, C(O)NR6R7, S(O)2NR6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R1, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
R6 and R7 are each independently selected from H, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic; or R6 and R7, together with the atoms to which they are attached, optionally form 4-8 membered heterocyclic;
R8 and R9 are each independently selected from H, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic; or R8 and R9, together with the atoms to which they are attached, optionally form 4-8 membered heterocyclic;
each R11 is independently selected from H, halogen, cyano, OR6, NR6R7, C(O)OR8, C(O)NR8R9, S(O)2NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R11, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
each R12 is independently selected from H, halogen, cyano, OR6, N6R7, C(O)OR6, C(O)NR6R7, S(O)2N6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R12, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
n is 0, 1, 2, 3, or 4;
m is 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9; and
x is 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9; and
pharmaceutically acceptable salts or tautomers thereof.

### Claim 13 (depends on 12)

The USP2 inhibitor of claim 12, wherein the compound is a compound of Formulae (I-B1-3), (I-B2-3) or (I-B3-3):
wherein
Ar2 is selected from C6-C10 aryl, or 5-10 membered heteroaryl;
each R13 is independently selected from H, halogen, cyano, OR6, NR6R7, C(O)OR6, C(O)NR6R7, S(O)2NR6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R13, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
X is CH or N;
Z is C═O or SO2;
R1 is selected from H, halogen, cyano, oxo, OR6, NR6R7, C(O)OR6, C(O)NR6R7, S(O)2NR6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R1, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
R6 and R7 are each independently selected from H, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic; or R6 and R7, together with the atoms to which they are attached, optionally form 4-8 membered heterocyclic;
R8 and R9 are each independently selected from H, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic; or R8 and R9, together with the atoms to which they are attached, optionally form 4-8 membered heterocyclic;
each R11 is independently selected from H, halogen, cyano, OR6, NR6R7, C(O)OR8, C(O)NR8R9, S(O)2NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R11, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
each R12 is independently selected from H, halogen, cyano, OR6, NR6R7, C(O)OR6, C(O)NR6R7, S(O)2NR6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R12, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
n is 0, 1, 2, 3, or 4;
m is 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9; and
x is 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9; and
pharmaceutically acceptable salts or tautomers thereof.

### Claim 14 (depends on 13)

The USP2 inhibitor of claim 13, wherein the compound is a compound of Formulae (I-B1-4), (I-B2-4) or (I-B3-4):
wherein
Ar2 is selected from C6-C10 aryl, or 5-10 membered heteroaryl;
Z is C═O or SO2;
each R13 is independently selected from H, halogen, cyano, OR6, NR6R7, C(O)OR6, C(O)NR6R7, S(O)2NR6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R13, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
R1 is selected from H, halogen, cyano, oxo, OR6, NR6R7, C(O)OR6, C(O)NR6R7, S(O)2NR6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R1, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
R6 and R7 are each independently selected from H, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic; or R6 and R7, together with the atoms to which they are attached, optionally form 4-8 membered heterocyclic;
R8 and R9 are each independently selected from H, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic; or R8 and R9, together with the atoms to which they are attached, optionally form 4-8 membered heterocyclic;
each R11 is independently selected from H, halogen, cyano, OR6, NR6R7, C(O)OR8, C(O)NR8R9, S(O)2NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R11, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
each R12 is independently selected from H, halogen, cyano, OR6, NR6R7, C(O)OR6, C(O)NR6R7, S(O)2NR6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R12, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
n is 0, 1, 2, 3, or 4;
m is 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9; and
x is 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9; and
pharmaceutically acceptable salts or tautomers thereof.

### Claim 15 (depends on 14)

The USP2 inhibitor of claim 14, wherein the compound is a compound of Formulae (I-B1-5), (I-B2-5) or (I-B3-5):
wherein
Ar2 is selected from C6-C10 aryl, or 5-10 membered heteroaryl;
Z is C═O or SO2;
each R13 is independently selected from H, halogen, cyano, OR6, NR6R7, C(O)OR6, C(O)NR6R7, S(O)2NR6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R13, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
R1 is selected from H, halogen, cyano, oxo, OR6, NR6R7, C(O)OR6, C(O)NR6R7, S(O)2NR6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R1, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
R6 and R7 are each independently selected from H, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic; or R6 and R7, together with the atoms to which they are attached, optionally form 4-8 membered heterocyclic;
R8 and R9 are each independently selected from H, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic; or R8 and R9, together with the atoms to which they are attached, optionally form 4-8 membered heterocyclic;
each R11 is independently selected from H, halogen, cyano, OR6, NR6R7, C(O)OR8, C(O)NR8R9, S(O)2NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R11, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
each R12 is independently selected from H, halogen, cyano, OR6, NR6R7, C(O)OR6, C(O)NR6R7, S(O)2NR6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R12, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
n is 0, 1, 2, 3, or 4;
m is 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9; and
x is 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9; and
pharmaceutically acceptable salts or tautomers thereof.

### Claim 16 (depends on 15)

The USP2 inhibitor of claim 15, wherein the compound is a compound of Formulae (I-B2-6) or (I-B2-7):
wherein
EWG is an electron withdrawing group;
X is CH or N;
Z is C═O or SO2;
Ar2 is selected from C6-C10 aryl, or 5-10 membered heteroaryl;
each R13 is independently selected from H, halogen, cyano, OR6, NR6R7, C(O)OR6, C(O)NR6R7, S(O)2NR6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R13, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
R1 is selected from H, halogen, cyano, oxo, OR6, NR6R7, C(O)OR6, C(O)NR6R7, S(O)2NR6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R1, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
R6 and R7 are each independently selected from H, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic; or R6 and R7, together with the atoms to which they are attached, optionally form 4-8 membered heterocyclic;
R8 and R9 are each independently selected from H, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic; or R8 and R9, together with the atoms to which they are attached, optionally form 4-8 membered heterocyclic;
n is 0, 1, 2, 3, or 4;
m is 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9; and
x is 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9; and
pharmaceutically acceptable salts or tautomers thereof.

### Claim 17 (depends on 16)

A compound according to claim 16, wherein the EWG is selected from the group consisting of halogen, cyano, C(O)OR6, C(O)NR6R7, S(O)2NR6R7, and C1-C6 haloalkyl.

### Claim 18 (depends on 16)

The USP2 inhibitor of claim 16, wherein the compound is a compound of Formulae (I-B2-8), (I-B2-9), (I-B2-10), (I-B2-11), (I-B2-12), (I-B2-13), (I-B2-14), (I-B2-15), (I-B2-16) or (I-B2-17):
wherein
Ar2 is selected from C6-C10 aryl, or 5-10 membered heteroaryl;
each R13 is independently selected from H, halogen, cyano, OR6, NR6R7, C(O)OR6, C(O)NR6R7, S(O)2NR6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R13, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
R1 is selected from H, halogen, cyano, oxo, OR6, NR6R7, C(O)OR6, C(O)NR6R7, S(O)2NR6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R1, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
R6 and R7 are each independently selected from H, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic; or R6 and R7, together with the atoms to which they are attached, optionally form 4-8 membered heterocyclic;
R8 and R9 are each independently selected from H, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic; or R8 and R9, together with the atoms to which they are attached, optionally form 4-8 membered heterocyclic;
n is 0, 1, 2, 3, or 4;
m is 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9; and
x is 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9; and
pharmaceutically acceptable salts or tautomers thereof.

### Claim 19

A USP2 inhibitor, comprising a compound of Formulae (I-C1), (I-C2) or (I-C3).
wherein
A is C═O, CH2 or absent;
Y is a bond, or a bivalent moiety selected from —N(R4)—, —N(R4)—C1-C3 alkylene-, —N(R4)—S(O)2—, —N(R4)—C(O)—, —S(O)2— N(R4)—, or —C(O)—N(R4)—;
Ring D is a ring structure selected from C5-C10 aryl, 5-10 membered heteroaryl or 3-12 membered heterocyclic;
Ar2 is selected from C6-C10 aryl, or 5-10 membered heteroaryl;
Ar3 is selected from 7-10 membered bicyclic heteroaryl;
Ar4 is selected from 5-6 membered monocyclic heteroaryl;
Ar5 is selected from C6-C10 aryl, or 5-10 membered heteroaryl;
Q1 and Q2 are independently selected from absent, O, NR5, C1-C3 alkylene, C2-C6 alkenylene, or C2-C6 alkynylene, where each said C1-C3 alkylene, C2-C6 alkenylene, or C2-C6 alkynylene is optionally substituted with one or more of halogen, cyano, hydroxyl, oxo, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxyl, or C3-C6 cycloalkoxy;
R1 is independently selected from H, halogen, cyano, oxo, OR6, NR6R7, C(O)OR6, C(O)NR6R7, S(O)2NR6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R1 together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
each R4, each R5, each R6 and each R7 are independently selected from H, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic; or R6 and R7, together with the atoms to which they are attached, optionally form 4-8 membered heterocyclic;
each R8 and each R9 are independently selected from H, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-Cia aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic; or R8 and R9, together with the atoms to which they are attached, optionally form a 4-8 membered heterocyclic;
R10 is selected from H, OR6, NR6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl;
each R11 is independently selected from H, halogen, cyano, OR6, NR6R7, C(O)OR8, C(O)NR8R9, S(O)2NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R11, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
and
n is 0, 1, 2, 3, or 4;
m is 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9; and
pharmaceutically acceptable salts or tautomers thereof.

### Claim 20

A USP2 inhibitor, comprising a compound of Formulae (I-C1-1), (I-C2-1), (I-C3-1), (I-C1-2), (I-C2-2) or (I-C3-2):
wherein
Ar2 is selected from C6-C10 aryl, or 5-10 membered heteroaryl;
Ar3 is selected from 7-10 membered bicyclic heteroaryl;
Ar4 is selected from 5-6 membered monocyclic heteroaryl;
Ar5 is selected from C6-C10 aryl, or 5-10 membered heteroaryl;
R1 is independently selected from H, halogen, cyano, oxo, OR6, N6R7, C(O)OR6, C(O)NR6R7, S(O)2N6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R1 together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
each R11 is independently selected from H, halogen, cyano, OR6, NR6R7, C(O)OR8, C(O)NR8R9, S(O)2NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R11, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
each R12 is independently selected from H, halogen, cyano, OR6, NR6R7, C(O)OR6, C(O)NR6R7, S(O)2NR6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R12, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
R6 and R7 are each independently selected from H, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic; or R6 and R7, together with the atoms to which they are attached, optionally form 4-8 membered heterocyclic;
R8 and R9 are each independently selected from H, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic; or R8 and R9, together with the atoms to which they are attached, optionally form 4-8 membered heterocyclic;
each R13 is independently selected from H, halogen, cyano, OR6, NR6R7, C(O)OR6, C(O)NR6R7, S(O)2NR6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R13, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
n is 0, 1, 2, 3, or 4;
m is 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9;
x is 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9; and
pharmaceutically acceptable salts or tautomers thereof.

### Claim 21 (depends on 20)

The USP2 inhibitor of claim 20, wherein the compound is a compound of Formulae (I-C2-3), or (I-C2-4):
wherein,
Ar2 is selected from C6-C10 aryl, or 5-10 membered heteroaryl;
R1 is independently selected from H, halogen, cyano, oxo, OR6, NR6R7, C(O)OR6, C(O)NR6R7, S(O)2NR6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R1 together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
each R12 is independently selected from H, halogen, cyano, OR6, NR6R7, C(O)OR6, C(O)NR6R7, S(O)2NR6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R12, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
R6 and R7 are each independently selected from H, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic; or R6 and R7, together with the atoms to which they are attached, optionally form 4-8 membered heterocyclic;
R8 and R9 are each independently selected from H, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, or 3-12 membered heterocyclic; or R8 and R9, together with the atoms to which they are attached, optionally form 4-8 membered heterocyclic;
each R13 is independently selected from H, halogen, cyano, OR6, NR6R7, C(O)OR6, C(O)NR6R7, S(O)2NR6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R13, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
n is 0, 1, 2, 3, or 4;
x is 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9; and
pharmaceutically acceptable salts or tautomers thereof.

### Claim 22 (depends on 21)

The USP2 inhibitor of claim 21, wherein the compound is a compound of Formulae (I-C2-5) or (I-C2-6):
wherein
EWG is an electron withdrawing group;
R1 is selected from H, halogen, cyano, oxo, OR6, NR6R7, C(O)OR6, C(O)NR6R7, S(O)2N6R7, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl, where each said C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl is optionally substituted with halogen, cyano, oxo, OR8, NR8R9, C(O)OR8, C(O)NR8R9, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C12 cycloalkyl, 3-12 membered heterocyclic, C6-C10 aryl, or 5-10 membered heteroaryl; or two adjacent R1, together with the atoms to which they are attached, optionally form C4-C6 cycloalkyl or 5-7 membered heterocyclic, where each said C3-C6 cycloalkyl or 5-7 membered heterocyclic is optionally substituted with C1-C6 alkyl;
n is 0, 1, 2, 3, or 4; and
pharmaceutically acceptable salts or tautomers thereof.

### Claim 23

(canceled)

### Claim 24

A USP2 inhibitor, comprising a compound selected from the group consisting of:
XH153-182
4-fluoro-2-((4- methylphenyl) sulfonamido)- N-(thiazol-2- yl)benzamide
XH161-172 (MS1172)
N-(4-(4- bromophenyl)thiazol-2- yl)-4-fluoro-2-((1- methylethyl) sulfonamido)benzamide
XH161-180 (MS1180)
N-(4-(4- bromophenyl)thiazol-2- yl)-2- (cyclohexane- sulfonamido)- 4-fluorobenzamide
XH208-93P2
4-Fluoro-N-(4-(4- fluorophenyl)thiazol-2- yl)-2-(4- (trifluoromethyl) benzamido) benzamide
XH208-94P2
N-(4-(4- Chlorophenyl)thiazol-2- yl)-4-fluoro-2-(4- (trifluoromethyl) benzamido) benzamide
XH198-68P2
4-Fluoro-N-(4-(4- fluorophenyl)thiazol-2- yl)-2-(2,2,2- trifluoroacetamido) benzamide
XH188-135p1
3-(4-(4- Bromophenyl)thiazol-2- yl)-7-fluoro-2- (trifluoromethyl) quinazolin-4(3H)-one
XH188-135p2
N-(4-(4- Bromophenyl)thiazol-2- yl)-4-fluoro-2-(2,2,2- trifluoroacetamido) benzamide
XH161-102 (MS102)
N-(4-(4- bromophenyl)thiazol- 2-yl)-2-((4- methylphenyl) sulfonamido)-5- (trifluoromethyl) benzamide
and pharmaceutically acceptable salts or tautomers thereof.

### Claim 25 (depends on 1)

A pharmaceutical composition, comprising:
a USP2 inhibitor according to claim 1, and a pharmaceutically acceptable carrier.

### Claim 26

(canceled)

### Claim 27 (depends on 25)

A pharmaceutical composition according to claim 25, wherein the composition is formulated for administration by oral, parenteral or transdermal delivery.

### Claim 28 (depends on 1)

A method of treating a USP2-mediated disease, comprising administering to a subject in need thereof an USP2 inhibitor according to claim 1.

### Claim 29 (depends on 28)

A method according to claim 28, wherein the disease is selected from mesothelioma, hepatocellular cancer, central nervous system neoplasm, lung cancer, bone cancer, pancreatic cancer, skin cancer, head and neck cancer, melanoma, ovarian cancer, colon cancer, rectal cancer, anal cancer, stomach cancer, gastrointestinal cancer, breast cancer), uterine cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, esophageal cancer, gastrointestinal cancer, endocrine cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, testicular cancer, leukemia, lymphoma, bladder cancer, renal cell cancer, brain stem glioma, pituitary cancer, adrenocortical cancer, gallbladder cancer, multiple myeloma, cholangiocarcinoma, fibrosarcoma, neuroblastoma, and retinoblastoma.

### Claim 30 (depends on 1)

A method of treating a USP2-mediated virus infection including hCoV-NL63, SARS-CoV-1 and SARS-CoV-2, comprising administering to a subject in need thereof an USP2 inhibitor according to claim 1.

### Claim 31 (depends on 28)

A method according to claim 28, wherein the inhibitor is administered orally, parenterally, intradermally, subcutaneously, topically, and/or rectally.

### Claim 32 (depends on 31)

A method according to claim 31, further comprising an additional therapeutic regimen selected from of surgery, chemotherapy, radiation therapy, hormone therapy, or immunotherapy.
